Paeds Cases · gastroenterology-hepatology-and-nutrition
Non-alcoholic fatty liver disease in children — structured clinical encounter
Structured encounter testing the approach to an eleven-year-old overweight boy found on screening to have a mildly raised alanine aminotransferase: recognising the misleading laboratory range, applying the NASPGHAN sex-specific thresholds, confirming persistence, excluding mimics, delivering family-based lifestyle therapy, and framing the cardiovascular-predominant prognosis.
On this page
Study tools
Target exams
Station brief (candidate)
You are the paediatric registrar in a general paediatric clinic. An eleven-year-old boy is reviewed at a routine visit. His body mass index is on the ninety-second percentile. He drinks two cans of sugar-sweetened soft drink a day, plays no organised sport, and spends most evenings on a screen. His alanine aminotransferase is 34 units per litre, and the laboratory reports its normal range as up to 55 units per litre. His father has type 2 diabetes. The team asks you to interpret the result, state the relevant thresholds, outline the confirmation and exclusion pathway, and deliver the management and family-counselling plan. You have twelve minutes with the team and five minutes for examiner discussion. [1]
References5ShowHide
- [1]Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr, 2017.PMID 28107283
- [3]Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA, 2011.PMID 21521847
- [4]Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol, 2023.PMID 37364790
- [6]Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al Guidelines on the management of abnormal liver blood tests. Gut, 2018.PMID 29122851
- [8]Sood V, Alam S, Nagral A, Srivastava A, Deshmukh A, Bavdekar A, et al Practice Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease by the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition (ISPGHAN). Indian Pediatr, 2024.PMID 39297398